Shannon Grabosch, MD
Gynecologic Oncology · Saint Louis, MONPI 1003136151
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $8,100 of the $9,448 with a category attached, or 85.7%. AstraZeneca accounts for 88.7% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2021 at $7,291 and has fallen 99.3% since, to $48 in 2025.
Across 40 payments — averaging $236.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$8K
- Conmed Corporation$300
- Tesaro, Inc.$190
- Clovis Oncology, Inc.$179
- GSK$130
- Intuitive Surgical$129
- plus $139 from 4 others
What the payments were for
- Consulting fees$3003%
- Speaking & faculty fees$8,10086%
- Travel & lodging$1161%
- Food & beverage$8169%
- Education$1151%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 8 | $8,380 |
| Conmed Corporation | 1 | $300 |
| Tesaro, Inc. | 4 | $190 |
| Clovis Oncology, Inc. | 13 | $179 |
| GSK | 6 | $130 |
| Intuitive Surgical | 1 | $129 |
| Merck | 4 | $83 |
| Eisai Inc. | 1 | $25 |
| Myriad Genetic Laboratories, Inc. | 1 | $20 |
| Cumberland Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYNPARZA$8,341
- Da Vinci Surgical System$129
- ZEJULA$125
How this compares
$9,448 in reported general payments places this provider in the 75th percentile of 38 gynecologic oncology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Megestrol Acetate | 31 | $1,100 |
| Duloxetine Hcl | 50 | $1,035 |
| Ondansetron Hcl | 37 | $1,014 |
| Gabapentin | 35 | $456 |
| Oxycodone Hcl | 40 | $306 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 20 | $258 |
| Mirtazapine | 23 | $252 |
| Ibuprofen | 22 | $215 |
| Potassium Chloride | 16 | $111 |
| Dexamethasone | 19 | $66 |
| Lorazepam | 33 | $50 |
| Folic Acid | 11 | $29 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Saint Louis
- Premal ThakerSaint Louis$287K
- Matthew PowellSaint Louis$162K
- David MutchSaint Louis$26K
- Dan-Arin SilasiSaint Louis$23K
- Dineo KhabeleSaint Louis$22K
- Carolyn McCourtSaint Louis$14K
- Andrea HagemannSaint Louis$11K
- Randall GibbSaint Louis$8K
- Leslie MassadSaint Louis$6K
- Madhavi ManyamSaint Louis$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.